Radius is a scientifically-driven fully integrated pharmaceutical organization dedicated to advancing and marketing innovative hormone-related therapies. The company's primary product, TYMLOS® (abaloparatide) injection, has received approval from the U.S. Food and Drug Administration for treating postmenopausal women with osteoporosis who are at high risk of fractures. Radius' ongoing research includes exploring the potential use of abaloparatide injection for men with osteoporosis and a patch for postmenopausal women with osteoporosis.